Nanomi is a leading brand in the field of microsphere and nanoparticle manufacture and the development of long-acting release medicines. With a focus on high-quality research and the utilization of their proprietary Microsieve technology, Nanomi has positioned itself as a pioneer in the industry. Their cutting-edge Microsieve technology ensures the production of medicines with uniform particle size, shape, and biological properties, allowing for precise dosing over extended periods.

This robust and scalable technology has a wide range of applications and offers unprecedented potential for the development of long-acting release medicines. As a member of the Lupin group, Nanomi aligns with their parent company's culture of innovation, integrity, and operational excellence. Lupin, a global pharmaceutical company, operates in over 100 countries and is committed to the development of affordable high-quality medicines.

Nanomi connects with this vision by setting world-class manufacturing standards and focusing on the development of complex injectables, particularly in areas of unmet needs. The mission of Nanomi is to become a leader in complex injectables by introducing a broad portfolio of branded and generic products in key markets. They are dedicated to improving the health and well-being of individuals by providing complex injectables to healthcare professionals.

With a strong commitment to integrity, excellence, teamwork, entrepreneurial spirit, respect, care, and customer focus, Nanomi prioritizes delivering outstanding results and building long-term partnerships with stakeholders